Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Open accessThe DOI matches its Crossref record; 119 of the 121 references it cites were found in a registry or an index.
Abstract
The use of low-density lipoprotein cholesterol (LDL-C)-lowering medications has led to a significant reduction of cardiovascular risk in both primary and secondary prevention. Statin therapy, one of the cornerstones for the prevention and treatment of cardiovascular disease (CVD), has been demonstrated to be effective in lowering LDL-C levels and in reducing the risk for CVD and is generally well-tolerated. However, compliance with statins remains suboptimal. One of the main reasons is limitations by adverse events, notably myopathies, which can lead to non-compliance with the prescribed statin regimen. Reducing the burden of elevated LDL-C levels is critical in patients with CVD as well as in patients with very high baseline levels of LDL-C (e.g. patients with familial hypercholesterolaemia), as statin therapy is insufficient for optimally reducing LDL-C below target values. In this review, we discuss alternative treatment options after maximally tolerated doses of statin therapy, including ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and cholesteryl ester transfer protein (CETP) inhibitors. Difficult-to-treat patients may benefit from combination therapy with ezetimibe or a PCSK9 inhibitor (evolocumab or alirocumab, which are now available). Updates of treatment guidelines are needed to guide the management of patients who will best benefit from these new treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Trafficking of LDLR in the presence of PCSK9 (a) or following PCSK9 inhibition by a monoclonal antibody (b). a Secreted PCSK9 binds to LDLR on the liver cell surface and mediates the lysosomal degradation of the complex formed by PCSK9, LDLR, and LDL [68]. b In the presence of a monoclonal antibody that binds to PCSK9, the PCSK9-mediated degradation of LDLR is inhibited, resulting in an increased uptake of LDL-cholesterol by LDLR as more LDLR are recycled at the cell surface [72]. LDL low-density lipoprotein, LDLR low-density lipoprotein receptor, PCSK9 proprotein convertase subtilisin/kexin type 9](https://figures.cochat.ai/paper-figures/99fbd173f3c3431fb3ebcd58e134e201/unmet-needs-in-ldl-c-lowering-when-statins-wont-do-figure-1.jpg)
![Fig. 2 Impact of statins on cholesterol metabolism. Statins inhibit the biosynthesis of intracellular cholesterol by inhibiting HMG-CoA reductase. This results in low levels of intracellular cholesterol, leading to increased SREBP-2 activity, which promotes the production of PCSK9 and LDLR, the degradation of which is mediated by PCSK9 [72]. HMG CoA 3-hydroxy-3-methyl-glutaryl-CoA, LDL low-density lipoprotein, LDLR low density lipoprotein receptor, mRNA messenger RNA, PCSK9 proprotein convertase subtilisin/kexin type 9, SREBP-2 sterol-regulatory element-binding protein](https://figures.cochat.ai/paper-figures/aeafb13aac6a48b0b2884919e195edf0/unmet-needs-in-ldl-c-lowering-when-statins-wont-do-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a consequence, multiple authors have concluded that there is a significant unmet medical need for patients with dyslipidaemia to reduce blood lipid levels to prevent the incidence of adverse cardiovascular events [26–30].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary choice of statins works well due to their effectiveness and safety as well as affordability, but they fail to meet LDL-C goals or are poorly tolerated by patients [74–76].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491 · cited 1×
“Most guidelines use risk estimation systems based on either the Framingham or the SCORE projects [2, 14, 15].”
MethodThe metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290 · cited 1×
“Most guidelines use risk estimation systems based on either the Framingham or the SCORE projects [2, 14, 15].”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · cited 7×
“Additionally, individuals with loss-of-function mutations in PCSK9 were found to have reduced plasma levels of LDLC and to be protected from CHD [69, 74].”
BackgroundInfluentialNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Research works printed but not linked: 6
- European Cardiovascular Disease Statistics 2012 edition. http://www.escardio.org/The-ESC/Initiatives/EuroHeart/2012-European-Cardiovascular-Disease-Statistics . Last accessed Jan 2016.
- Golomb B, Yang E, Denenberg J, et al. Statin-associated muscle adverse effects. Circulation. 2003;107:e7028–9.
- Dorey E. Cholesterol-busting PCSK9 drugs. Pharm J. 2015. http://www.pharmaceutical-journal.com/news-and-analysis/features/pcsk9-inhibitors-the-next-cholesterol-lowering-blockbusters/20068181.article . Last accessed Jan 2016.
- Ginsberg HN, Rader DJ, Raal FJ. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Circulation. 2014;130:2119.
- Roth E, Rader DJ, Moriarty P. Phase 3 randomized trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I. Abstract no. 0254 presented at 17th International Symposium on Atherosclerosis. 2015.
- Stroes E, Guyton J, Farnier M. Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. Abstract no. 0269 presented at 17th International Symposium on Atherosclerosis. 2015.
Cited by
Wright, R. S., Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Friedman, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.058 · Cited by 229
Mechanisms of statin-associated skeletal muscle-associated symptoms
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.010 · Cited by 136
Self-citationAlleyne, C., Amin, R. P., Bhatt, B., Bianchi, E., Blain, J. C., Boyer, N., Branca, D., Embrey, M. W., Ha, S. N., Jette, K., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01084 · Cited by 131
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Amino Acids and Their Metabolism in Atherosclerosis
Nitz, K., Lacy, M., & Atzler, D. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311572 · Cited by 113
Metadata
- Authors
- Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A.
- Affiliations
- University of Basel (CH)
- Amgen (Switzerland) (CH)
- Corresponding author
- Krähenbühl, Stephan
- ORCID
- Krähenbühl, Stephan
- Venue
- Drugs
- Published
- 2016-07-25
- Volume
- 76
- Issue
- 12
- Pages
- 1175-1190
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC4974266
- OpenAlex
- W2496801530
- Semantic Scholar
- 7f30ae4aa52afa3ab98b84823e58b05b6cddea29
- Cited by
- 89
- References
- 121
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 11 · 2023: 10 · 2022: 9 · 2021: 15 · 2020: 7 · 2019: 7 · 2018: 8 · 2017: 5
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- edoc (University of Basel) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Funded by the institutions of the authors
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- LDL cholesterol lowering, statin therapy, statin adverse effects, statin-induced myopathy, familial hypercholesterolemia, ezetimibe, PCSK9 inhibitors, evolocumab, alirocumab, CETP inhibitors, combination therapy, cardiovascular risk reduction, hypercholesterolemia
- MeSH terms
- Ezetimibe, Cardiovascular Diseases, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Subtilisin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unmet Needs in LDL-C Lowering: When Statins Won’t Do! https://app.cochat.ai/papers/10.1007/s40265-016-0613-0
- The paper
- Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016). Unmet Needs in LDL-C Lowering: When Statins Won’t Do! Drugs. https://doi.org/10.1007/s40265-016-0613-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.